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MEMBERS SUPPORT DEVELOPMENT
OF OUTCOME MEASUREMENTS
ASBMT members have voiced
strong support for their society devel-
oping measures of treatment out-
comes, provided that those measures
are accurate, useful and fairly ap-
plied.
In an online survey, members were
asked their opinions about efforts to
create a standardized system for mea-
suring and reporting outcomes of he-
matopoietic cell therapy. A strategy
and the reasons for the effort were
outlined in a “white paper” published
in the May 2006 issue of Biology of
Blood and Marrow Transplantation.
Among the survey findings:
● 96% said that the society should
provide advice to government
agencies and third-party payers
on the development of measures
of treatment outcomes.
● 89% said that the society should
develop a model protocol for the
comprehensive measurement and
reporting of center-specific treat-
ment outcomes.
● 83% said that the society-devel-
oped protocol should include
both autologous and allogeneic
transplants.
● 94% agreed with an approach to
outcome measurement that
would recognize the diversity of
individual programs, be based on
quality assurance and improve-
ment, and minimize the adminis-
trative burdens of data collection.
● “It was gratifying to see the num-
ber of members who provided
thoughtful comments and obser-
vations to the open-end question
at the end of the survey,” said Roy
Jones, MD, chair of the ASBMT
Committee on Hematopoietic Cell
Transplant Quality Outcomes. His
committee authored the white pa-
per that laid out the reasons for
developing outcome measures at
this time:
● The recently enacted Stem Cell
Therapeutic and Research Act of
2005 will require all U.S. centers
performing allogeneic transplants
to begin reporting each alloge-
neic transplant patient’s outcome
to a central registry.
● Third-party payers have expressed
a desire to have more detailed
treatment outcome information
for reimbursement decisions and
for designating centers of excel-
lence. Some already are moving in
this direction.
● The Outcomes Committee has de-
termined that valid outcome mea-
sures from transplant centers can
be determined only through com-
prehensive confidential reporting
of individual patient data to a cen-
tral registry.
● Patients and referring physicians
increasingly are seeking treatment
outcome information for making
informed decisions about health
care.
● Solid organ transplants already
have a sophisticated system for
measuring and reporting treat-
ment outcomes through compre-
hensive collection of individual pa-
tient data.
● The white paper takes the position
that ASBMT should become in-
volved in the development of pro-
tocol for center-specific treatment
outcome measurement and re-
porting because the alternative is
measurement systems that are im-
posed by entities outside the BMT
community.
BBMT MANUSCRIPT ARRIVALS
EXCEEDING ONE PER DAY
Only two or three manuscripts
trickled in per month in the early days
of Biology of Blood and Marrow
Transplantation. Now, during a typi-
cal workweek, they arrive at the rate
of more than one a day.
The dramatic growth in manuscript
submissions can be tracked in the per-
month arrivals since the journal’s
founding:
1995 2.8 2001 9.3
1996 3.7 2002 8.6
1997 4.5 2003 11.8
1998 4.5 2004 13.6
1999 6.7 2005 20.5
2000 7.6 2006 25.6
“When the journal was launched,
ASBMT founders were cautioned that
it would take years to establish a new
medical journal and that the publish-
ing landscape was littered with failed
startups,” said Daniel Weisdorf, MD,
chair of the ASBMT Publications Com-
mittee.
“Clinicians and investigators al-
ways want to send their work to
journals with an established reputa-
tion and readership,” he said. “We
certainly demonstrated the truth of
that.”
“Last year the manuscript rejection
rate was 38%,” said Editor-in-Chief
Robert Korngold, PhD. “That rate has
been fairly consistent over the past
three years. To accommodate the
growing number of manuscripts, the
size of the journal has continued to
grow.”
The ISI Impact Factor for BBMT, a
measure of the frequency of citations
of its articles in the literature, has con-
tinued to climb to 3.561. That places
it fourth among 20 transplant jour-
nals, 16th among 60 hematology
journals, and 28th among 114 immu-
nology journals.
The journal lost money and was
heavily subsidized by the Society in its
early years. Since 2002, it has
achieved a revenue surplus.
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